{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:54Z","timestamp":1787009454391,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["ISS 20159990"],"award-info":[{"award-number":["ISS 20159990"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Since giant cell tumors of bone (GCTB) and other giant cell rich tumors of bone (GCRTB) share the histological presence of osteoclastic giant cells and expression of RANK\/RANKL, we hypothesized that GCRTB will respond similarly to denosumab as GCTB. The primary objective of this study was to determine the efficacy of denosumab in patients with GCRTB that have recurred or require morbid surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this open-label, multicenter, phase II trial, patients with GCRTB were included (June 2018-March 2020). Recruitment was stopped because of low accrual. Patients received denosumab (120 mg) subcutaneously (SC) on day 1 of every 4-week cycle with a loading dose of 120 mg SC on days 8 and 15.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three patients were enrolled. One withdrew consent before start of study. The remaining patients had central giant cell granuloma of the jawbone (CGCG). Median treatment duration was 15 cycles (range 12-18). In both subjects, improvement in ossification of lesions was seen. Median follow-up was 28.5 months (range 20-37). One patient developed a recurrence for which surgery was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Due to critical emerging real-world data of denosumab in GCRTBs, the study was prematurely stopped and not supportive of use of denosumab for this indication. (ClinicalTrials.gov Identifier: NCT03605199).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad196","type":"journal-article","created":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T01:47:31Z","timestamp":1687657651000},"page":"1005-e1104","source":"Crossref","is-referenced-by-count":5,"title":["Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5400-1138","authenticated-orcid":false,"given":"Astrid","family":"Lipplaa","sequence":"first","affiliation":[{"name":"Medical Oncology, Leiden University Medical Center , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem H","family":"Schreuder","sequence":"additional","affiliation":[{"name":"Oral and Maxillofacial Surgery, Amsterdam UMC Location University of Amsterdam , Amsterdam , The Netherlands"},{"name":"Academic Center for Dentistry, University of Amsterdam , Amsterdam , The Netherlands"},{"name":"Head and Neck Surgery and Oncology, Antoni van Leeuwenhoek\/Netherlands Cancer Institute , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina E C","family":"Pichardo","sequence":"additional","affiliation":[{"name":"Oral and Maxillofacial Surgery, Leiden University Medical Center , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-8636","authenticated-orcid":false,"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[{"name":"Medical Oncology, Leiden University Medical Center , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"issue":"9","key":"2023110708522629700_CIT0001","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(13)70277-8","article-title":"Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study","volume":"14","author":"Chawla","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"2023110708522629700_CIT0002","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","article-title":"Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"2023110708522629700_CIT0003","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12957-018-1459-6","article-title":"Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study","volume":"16","author":"Urakawa","year":"2018","journal-title":"World J Surg Oncol"},{"issue":"11","key":"2023110708522629700_CIT0004","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1007\/s00264-017-3536-9","article-title":"How safe and effective is denosumab for bone giant cell tumour","volume":"41","author":"Errani","year":"2017","journal-title":"Int Orthop."},{"issue":"12","key":"2023110708522629700_CIT0005","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1302\/0301-620X.100B12.BJJ-2018-0189.R2","article-title":"Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture","volume":"100-B","author":"Medellin","year":"2018","journal-title":"Bone Joint J"},{"key":"2023110708522629700_CIT0006","doi-asserted-by":"crossref","first-page":"116395","DOI":"10.1016\/j.bone.2022.116395","article-title":"Denosumab for central giant cell granuloma in an Australian tertiary paediatric centre","volume":"159","author":"Vanderniet","year":"2022","journal-title":"Bone"},{"issue":"4","key":"2023110708522629700_CIT0007","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00223-021-00935-z","article-title":"Clinical and radiologic response of central giant cell granuloma to denosumab: a 6-year prospective observational study","volume":"110","author":"Rhou","year":"2022","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"2023110708522629700_CIT0008","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1634\/theoncologist.2013-0432","article-title":"The clinical approach toward giant cell tumor of bone","volume":"19","author":"van der Heijden","year":"2014","journal-title":"Oncologist"},{"issue":"3","key":"2023110708522629700_CIT0009","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/01.bpb.0000210588.50899.29","article-title":"Current treatments of primary aneurysmal bone cysts","volume":"15","author":"Cottalorda","year":"2006","journal-title":"J Pediatr Orthop B"},{"issue":"4","key":"2023110708522629700_CIT0010","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5435\/JAAOS-21-04-225","article-title":"Chondroblastoma and chondromyxoid fibroma","volume":"21","author":"De Mattos","year":"2013","journal-title":"J Am Acad Orthop Surg"},{"issue":"2","key":"2023110708522629700_CIT0011","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jbo.2015.02.001","article-title":"Benign tumours of the bone: a review","volume":"4","author":"Hakim","year":"2015","journal-title":"J Bone Oncol"},{"issue":"6","key":"2023110708522629700_CIT0012","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/PAS.0b013e31802fb498","article-title":"Novel karyotypes in giant cell-rich lesions of bone","volume":"31","author":"Gleason","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"2023110708522629700_CIT0013","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1359\/jbmr.081112","article-title":"Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL","volume":"24","author":"Kostenuik","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2023110708522629700_CIT0014","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"13","key":"2023110708522629700_CIT0015","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"issue":"13","key":"2023110708522629700_CIT0016","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria","volume":"25","author":"Choi","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023110708522629700_CIT0017","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singap"},{"issue":"6","key":"2023110708522629700_CIT0018","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00586-013-2715-7","article-title":"Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts","volume":"22","author":"Lange","year":"2013","journal-title":"Eur Spine J"},{"issue":"7","key":"2023110708522629700_CIT0019","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.joms.2014.02.017","article-title":"Alternative pharmacologic therapy for aggressive central giant cell granuloma: denosumab","volume":"72","author":"Schreuder","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"issue":"22","key":"2023110708522629700_CIT0020","doi-asserted-by":"crossref","first-page":"E1201","DOI":"10.1097\/BRS.0000000000001027","article-title":"Response of aneurysmal bone cyst to denosumab","volume":"40","author":"Skubitz","year":"2015","journal-title":"Spine (Phila Pa 1976)"},{"issue":"2","key":"2023110708522629700_CIT0021","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.trsl.2014.03.005","article-title":"Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response","volume":"164","author":"Pelle","year":"2014","journal-title":"Transl Res"},{"issue":"10","key":"2023110708522629700_CIT0022","doi-asserted-by":"crossref","first-page":"E601","DOI":"10.1097\/BRS.0000000000000862","article-title":"Effect of denosumab on recurrent giant cell reparative granuloma of the lumbar spine","volume":"40","author":"Akeda","year":"2015","journal-title":"Spine (Phila Pa 1976)"},{"issue":"7","key":"2023110708522629700_CIT0023","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.jcms.2015.04.011","article-title":"A novel approach to the management of a central giant cell granuloma with denosumab: a case report and review of current treatments","volume":"43","author":"Gupta","year":"2015","journal-title":"J Craniomaxillofac Surg"},{"issue":"12","key":"2023110708522629700_CIT0024","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1016\/j.joms.2014.06.456","article-title":"Management of central giant cell granuloma with subcutaneous denosumab therapy","volume":"72","author":"Naidu","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"2023110708522629700_CIT0025","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s12891-019-2855-y","article-title":"Aneurysmal bone cyst: results of an off label treatment with Denosumab","volume":"20","author":"Durr","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"issue":"2","key":"2023110708522629700_CIT0026","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4103\/ams.ams_192_18","article-title":"Denosumab treatment for aggressive multiple recurrent familial central giant-cell granulomas","volume":"8","author":"Rytkonen","year":"2018","journal-title":"Ann Maxillofac Surg"},{"issue":"7","key":"2023110708522629700_CIT0027","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bjoms.2019.05.023","article-title":"Management of an aggressive giant cell granuloma of the mandible with denosumab: a case report","volume":"57","author":"Hameed","year":"2019","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"6","key":"2023110708522629700_CIT0028","doi-asserted-by":"crossref","first-page":"e29436","DOI":"10.1002\/pbc.29436","article-title":"Treatment of central giant cell granuloma with denosumab: a case report of a complicated treatment course","volume":"69","author":"Brijs","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2023110708522629700_CIT0029","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.ijom.2020.12.013","article-title":"Denosumab for the management of central giant cell granuloma of the jaws-a case series","volume":"50","author":"Pogrel","year":"2021","journal-title":"Int J Oral Maxillofac Surg"},{"key":"2023110708522629700_CIT0030","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejca.2022.08.011","article-title":"RANKL inhibition for giant cell lesions of the jaw: a retrospective cohort analysis","volume":"175","author":"Schreuder","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"2023110708522629700_CIT0031","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1210\/jc.2017-02025","article-title":"Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumor of bone","volume":"103","author":"Uday","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"15","key":"2023110708522629700_CIT0032","doi-asserted-by":"crossref","first-page":"11021","DOI":"10.1200\/JCO.2016.34.15_suppl.11021","article-title":"Long-term treatment of giant cell tumors of bone (GCTB) with denosumab: a two institutions 8-year experience","volume":"34","author":"Chawla","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"2023110708522629700_CIT0033","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s11999-015-4249-2","article-title":"A high-grade sarcoma arising in a patient with recurrent benign giant cell tumor of the proximal tibia while receiving treatment with denosumab","volume":"473","author":"Aponte-Tinao","year":"2015","journal-title":"Clin Orthop Relat Res"},{"key":"2023110708522629700_CIT0034","doi-asserted-by":"crossref","first-page":"767198","DOI":"10.1155\/2015\/767198","article-title":"Two cases of sarcoma arising in giant cell tumor of bone treated with denosumab","volume":"2015","author":"Broehm","year":"2015","journal-title":"Case Rep Med"},{"issue":"11","key":"2023110708522629700_CIT0035","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/jjco\/hyx112","article-title":"Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab","volume":"47","author":"Tsukamoto","year":"2017","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"2023110708522629700_CIT0036","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.3892\/ol.2016.5246","article-title":"Denosumab treatment of inoperable or locally advanced giant cell tumor of bone","volume":"12","author":"Borkowska","year":"2016","journal-title":"Oncol Lett"},{"key":"2023110708522629700_CIT0037","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.humpath.2017.02.008","article-title":"Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls","volume":"63","author":"Roitman","year":"2017","journal-title":"Hum Pathol"},{"issue":"4","key":"2023110708522629700_CIT0038","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/CCO.0000000000000529","article-title":"Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone","volume":"31","author":"Lipplaa","year":"2019","journal-title":"Curr Opin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/11\/1005\/52772279\/oyad196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/11\/1005\/52772279\/oyad196.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T03:53:24Z","timestamp":1699329204000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/11\/1005\/7224189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,7,14]]},"published-print":{"date-parts":[[2023,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad196","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,7,14]]}}}